Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:SPRO) with a Overweight.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $7 p...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...
Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported Februar...
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...
